Genetic Markers of Cardiovascular Disease in Epilepsy

Key facts

Sponsor

Mayo Clinic

Principal Investigator

Virend K. Somers, MD PhD

Mayo Clinic

Enrollment

600 enrolled

Eligibility

18-50 years · All sexes

Timeline

2016 – 2031

Study locations (1)

• Mayo Clinic, Rochester, Minnesota, United States

Collaborators

American Heart Association

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Epilepsy syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT07531745
  ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
  Ionis Pharmaceuticals, Inc.
• ENROLLING BY INVITATIONNCT07555171
  EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment
  University of Chicago
• RECRUITINGPHASE3NCT07234695
  LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
  Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
• RECRUITINGNCT06967727
  Registry and Natural History of Epilepsy-Dyskinesia Syndromes
  Boston Children's Hospital
• RECRUITINGNCT07202494
  Integrating Metabolism, Connectivity, and Mesoscale Imaging at Ultra-high Field to Decipher Mechanisms of Resilience and Neurodegeneration in Neurological Diseases and Healthy Aging
  Assistance Publique Hopitaux De Marseille
• RECRUITINGNCT05524493
  High-field MR Imaging in Migraine, Visual Snow and Epilepsy
  University of Zurich
• RECRUITINGNANCT06847152
  Spatial Memory and Temporal Lobe Epilepsy
  Centre Hospitalier Metropole Savoie
• RECRUITINGNANCT06813612
  Effect of Cognitive Behavioral Play Intervention and Epilepsy
  IRCCS National Neurological Institute "C. Mondino" Foundation

See all trials for Epilepsy syndrome →